Key Points Pfizer has made significant progress in addressing some of its challenges. However, the company still has a rocky road ahead. Launching newer medicines could help Pfizer overcome the obstacles ahead. 10 stocks we like better than Pfizer › The past few years have been challenging for Pfizer (NYSE: PFE) . The company has faced macroeconomic problems, significantly lower sales from its coronavirus portfolio, and looming patent cliffs, including for its best-selling drug, the anticoagulant Eliquis. However, according to CEO Albert Bourla, Pfizer's headwinds are easing. Is he right? Image source: The Motley Fool. Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.